Management of Dyslipidemia with Unani Medicine

Randomized double blinded placebo controlled clinical study to evaluate the efficacy of Darchini (Cinnamomum zeylanicum Blume)in the Management of dyslipidemia

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024557

Enrollment

Registered

2020-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified

Interventions

Intervention1: Darchini (Cinnamomum zeylanicum Blume): Two tablets of 500 mg powder twice a day for 12 weeks.total of 2gm of powder per day. Control Intervention1: placebo: Two tablets of 500 mg powde

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 20-65 years. 2. Patient of all genders. 3. Patient willing to participate and sign the written informed consent. 4. Known cases of dyslipidemia with any one of the following ï?? Total Cholesterol Level >200 mg/dl ï?? Low-Density Lipoprotein Cholesterol Level >130mg/dl ï?? High-Density Lipoprotein <40mg/dl

Exclusion criteria

Exclusion criteria: 1.Age below 20 and above 65 years. 2.Serum Triglycerides Level >1000mg/dl. 3.Pregnant and lactating women 4.Patients suffering from CKD, CAD, CLD, thyroid disorder, active tuberculosis. 5.Uncontrolled DM ( HbA1C >7 ), uncontrolled Hypertension 6.Known case of immune-compromised status. 7.The patient using lipid-lowering drugs or dietary supplements with the last 3 months. 8.Oral contraceptives & corticosteroids. 9.Use of alcohol or any other drug abuse. 10.Neurological disorders like epilepsy or psychiatric disorders.

Design outcomes

Primary

Measure	Time frame
lipid profile, PT/INR, BMI, LP(a), appo(B), hsCRP, Antioxidant profile (Lp, appo, hsCRP, Antioxidant profile will be done as per the availability of funds) Timepoint: Day1, 84TH Day	—

Secondary

Measure	Time frame
CBC,ESR,LFT,KFT,Blood sugar fasting, HbA1C, Urine R/MTimepoint: 0 day,84th day.;ScreeningTimepoint: Thyroid profile,ECG	—

Countries

India

Contacts

Public ContactDr Azhar Jabeen

Jamia Hamdard

ajabin@jamiahamdard.ac.in9899315252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026